-The Times of India and other agencies WASHINGTON: United States President Donald Trump has promised to bring the cost of prescription drugs in the country "way down" and let other countries pay more for these medicines. If effected, Trump's new policy on prescription drugs, dicussed with his cabinet at the White House on Monday, could have grave implications for India. The US has long had a grouse with India over its patent...
More »SEARCH RESULT
Total Matching Records found : 85
Why NPPA didn't wait for govt to make knee implants 'essential' -Rema Nagarajan
-The Times of India In a first for a medical device, the public interest provision in the Drug Price Control Order (DPCO) 2013 was used by the National Pharmaceutical Pricing Authority to cap the price of knee implants. The NPPA cited "exorbitant prices being charged from patients in a non-regulated market" and "a failed market system where asymmetry of information between patient and the doctor has resulted into unethical practices and...
More »Govt may cap knee implant prices -Aesha Datta
-The Hindu Business Line Industry likely to meet officials today New Delhi: Patients with debilitating knee problems, requiring joint replacement surgeries, would soon regain spring in their steps. The National Pharmaceutical Pricing Authority (NPPA), which capped the prices of coronary stents in February, may cap the prices of knee implants soon. According to a source in the know of the developments, the price of knee implants is likely to be capped with just...
More »After cap, rise in complaints that hospitals hiking price of non-stent components -Deepak Patel
-The Indian Express Responding to specific queries on the issue, Bhupendra Singh, NPPA chairman, told The Indian Express that “examination of hospital records is in process”. AFTER the National Pharmaceutical Pricing Authority (NPPA) in February ordered a cap on the prices of coronary stents and directed hospitals to issue separate bills specifying their cost, the drug pricing watchdog has started receiving consumer complaints against hospitals which are allegedly hiking the prices...
More »Stents sold in Europe for less than Indian prices -Rema Nagarajan
-The Times of India Multinational stent companies claim that the ceiling price fixed by the National Pharmaceutical Pricing Authority (NPPA) is commercially unviable, but they are selling at far lower prices in much richer countries with smaller markets than India such as Germany, the UK, Italy and many other European countries. A look at the prices of stent brands in these countries shows that people in India have been defrauded of crores...
More »
